A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients von Ford, C C, Johnson, K P, Lisak, R P, Panitch, H S, Shifroni, G, Wolinsky, J S

Volltext

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate von Ford, C., Goodman, AD, Johnson, K., Kachuck, N., Lindsey, JW, Lisak, R., Luzzio, C., Myers, L., Panitch, H., Preiningerova, J., Pruitt, A., Rose, J., Rus, H., Wolinsky, J.

Volltext

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability von JOHNSON, K. P, BROOKS, B. R, VOLLMER, T, WEINER, L. P, WOLINSKY, J. S, COHEN, J. A, FORD, C. C, GOLDSTEIN, J, LISAK, R. P, MYERS, L. W, PANITCH, H. S, ROSE, J. W, SCHIFFER, R. B

Volltext

Influence of infection on exacerbations of multiple sclerosis von Panitch, Hillel S.

Volltext

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years von Johnson, K P, Brooks, B R, Ford, C C, Goodman, A, Guarnaccia, J, Lisak, R P, Myers, L W, Panitch, H S, Pruitt, A, Rose, J W, Kachuck, N, Wolinsky, J S

Volltext

Interferons in multiple sclerosis : a review of the evidence von PANITCH, H. S

Volltext

The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study von Bever, CT, Grattan, L, Panitch, HS, Johnson, KP

Volltext

Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration von Khan, O A, Xia, Q, Bever, C T, Johnson, K P, Panitch, H S, Dhib-Jalbut, S S

Volltext

The effect of interferon-β on mouse neural progenitor cell survival and differentiation von Hirsch, Marek, Knight, Julia, Tobita, Mari, Soltys, John, Panitch, Hillel, Mao-Draayer, Yang

Volltext

Exacerbations of multiple sclerosis in patients treated with gamma interferon von PANITCH, H. S, HALEY, A. S, HIRSCH, R. L, JOHNSON, K. P

Volltext

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS von Arnold, D. L., Campagnolo, D., Panitch, H., Bar-Or, A., Dunn, J., Freedman, M. S., Gazda, S. K., Vollmer, T.

Volltext

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange von Keegan, Mark, König, Fatima, McClelland, Robyn, Brück, Wolfgang, Morales, Yazmín, Bitsch, Andreas, Panitch, Hillel, Lassmann, Hans, Weinshenker, Brian, Rodriguez, Moses, Parisi, Joseph, Lucchinetti, Claudia F

Volltext

Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial von Bever, C T, Anderson, P A, Leslie, J, Panitch, H S, Dhib-Jalbut, S, Khan, O A, Milo, R, Hebel, J R, Conway, K L, Katz, E, Johnson, K P

Volltext

Concurrence of multiple sclerosis and brain tumor : Clinical considerations von KHAN, O. A, BAUSERMAN, S. C, ROTHMAN, M. I, ALDRICH, E. F, PANITCH, H. S

Volltext

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years von Johnson, K.P., Brooks, B.R., Ford, C.C., Goodman, A., Guarnaccia, J., Lisak, R.P., Myers, L.W., Panitch, H.S., Pruitt, A., Rose, J.W., Kachuck, N., Wolinsky, J.S.

Volltext

Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study von Panitch, Hillel, Miller, Aaron, Paty, Donald, Weinshenker, Brian

Volltext

Respiratory Care of the patient with duchenne muscular dystrophy: ATS Consensus statement von Finder, Jonathan D, Birnkrant, David, Carl, John, Farber, Harold J, Gozal, David, Iannaccone, Susan T, Kovesi, Thomas, Kravitz, Richard M, Panitch, Howard, Schramm, Craig, Schroth, Mary, Sharma, Girish, Sievers, Lisa, Silvestri, Jean M, Sterni, Laura

Volltext

Bronchiolitis in infants von Panitch, H B

Volltext

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial von Panitch, H, Goodin, D S, Francis, G, Chang, P, Coyle, P K, O'Connor, P, Monaghan, E, Li, D, Weinshenker, B

Volltext

Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial von Panitch, Hillel, Goodin, Douglas, Francis, Gordon, Chang, Peter, Coyle, Patricia, O'Connor, Paul, Li, David, Weinshenker, Brian

Volltext